๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Beijing

5484 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Automated Bone Age Estimation From Noncontrast Abdominal CT Using Deep Learning
NCT07162168Bone Aging, Osteoporosis Diagnosis
Peking University People's Hospital
Observational
3,000
Beijing
2024-09-01
Not yet open
Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
NCT06563778Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma
DrugsBrentuximab Vedotin·Decitabine·Bendamustine·Chidamide
Chinese PLA General Hospital
Phase 2
100
Beijing
2024-09-01
Active, closed
A Clinical Trial of Vascular Interventional Robotic System for Cerebral Angiography
NCT07182188Crerbral Angiography
Peking Union Medical College Hospital
Not applicable
660
Beijing
2024-09-01
Not yet open
Phase 1 Trial of KH801
NCT06364501Advanced Solid Tumors
Beijing Kanghong Biopharmaceutical Co., Ltd.
Phase 1
17
Beijing, Guangzhou, Jinan, Chengdu
2024-09-01
Recruiting
First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
NCT05188859Mesothelioma, Malignant, Mesothelioma, Malignant Pleural, Mesothelioma Malignant Advanced
DrugsAnlotinib·Sintilimab·Pemetrexed·Cisplatin
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
29
Taiyuan, Beijing
2024-09-01
Recruiting
Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.
NCT07044921Colorectal Cancer Metastatic
DrugsIrinotecan liposomes·Cetuximab
Chinese PLA General Hospital
Phase 2
30
Beijing
2024-09-01
Active, closed
Exploring the Expression Level of Cadherin 6 Protein (CDH6) in Primary Malignant Bone Tumor Specimens and Its Clinical Application in Prognosis Assessment
NCT06850506Sarcoma, Sarcoma, Bone, Ewing Sarcoma, Osteosarcoma
Peking University People's Hospital
Observational
70
Beijing
2024-09-01
Recruiting
Neural Mechanisms and Clinical Applications of DBS for Modulating Sleep Dysregulation in PD
NCT06914466Deep Brain Stimulation, Parkinson's Disease and Parkinsonism, Sleep Disorder
Xuanwu Hospital, Beijing
Observational
20
Beijing
2024-09-01
By invitation
A Study of the Efficacy and Safety of Non-ablative Fractional Laser in the Treatment of Thyroidectomy Scars
NCT07037264Scars After Surgical Intervention
Chinese Medical Association
Not applicable
120
Beijing
2024-09-01
By invitation
A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors
NCT06992687Solid Tumors
Shanghai Huaota Biopharmaceutical Co., Ltd.
Phase 1/2
30
Beijing
2024-09-01
Recruiting
Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT
NCT07166445Carcinoma, Renal Cell, Diagnostic Imaging, Pathology, Deep Learning
Peking University First Hospital
Observational
1,000
Beijing
2024-09-01
Recruiting
Hypofractionated Online Adaptive Radiotherapy of Breast Cancer
NCT06568705Breast Cancer
Peking Union Medical College Hospital
Phase 2
40
Beijing
2024-09-01
Recruiting
Fasting Effects on Metabolism and Immunity Study in Human
NCT06779201Fasting
Xuanwu Hospital, Beijing
Not applicable
30
Beijing
2024-09-01
By invitation
[68Ga]Ga-P17-079 in the Diagnosis and Treatment of Metastatic Prostate Cancer
NCT06864572Metastatic Prostate Cancer (mPC)
Peking Union Medical College Hospital
Phase EARLY_PHASE1
40
Beijing
2024-09-01
Recruiting
Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation
NCT06108414Atrial Fibrillation, Anticoagulant Adverse Reaction, Stroke, Major Adverse Cardiac Events
DrugRivaroxaban
China National Center for Cardiovascular Diseases
Phase 4
4,374
Beijing
2024-09-01
Recruiting
Establishment of Screening Pathway for High-Risk Population of Type 1 Diabetes
NCT07468474Type 1 Diabetes Mellitus
Peking University First Hospital
Observational
340
Beijing
2024-09-01
Not yet open
Deep Brain Stimulation of the Dentate Nucleus for Motor Rehabilitation After Stroke
NCT06498934Stroke, Upper Extremity Paresis
Beijing Municipal Administration of Hospitals
Not applicable
52
Beijing
2024-09-01
Not yet open
Cervical Cytology DNA Methylation for Cervical Cancer Screening
NCT06557954Cervical Cancer, DNA Methylation, Cytology, Human Papillomavirus Infection
Lei Li
Observational
30,000
Beijing
2024-09-01
Recruiting
177Lu-TATE-RGD in Patients With SSTR2 and Integrin ฮฑVฮฒ3 Positive Tumors
NCT06632873SSTR2 and Integrin ฮฑVฮฒ3 Positive Tumors
Peking Union Medical College Hospital
Phase EARLY_PHASE1
10
Beijing
2024-09-01
Recruiting
Golidocitinib Plus CHOP in Newly Diagnosed PTCL
NCT06739265Peripheral T-cell Lymphoma
DrugsCHOP·Golidocitinib
Peking Union Medical College Hospital
Phase 1/2
68
Beijing
2024-09-01
Not yet open
Clinical Multicenter Randomized Controlled Study of Simultaneous Cognitive Training With Transcranial Magnetic Stimulation in the Treatment of VaD-MCI Patients
NCT06470113VaD-MCI
Xuanwu Hospital, Beijing
Not applicable
164
Beijing
2024-09
Not yet open
Application of Cheek Acupuncture in Vaginal Tightening Surgery
NCT06587711Pain Vulva
The Plastic Surgery Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Not applicable
60
Beijing
2024-09
Not yet open
Clinical Multicenter Randomized Controlled Study of Non-invasive Brain Oscillation Modulation in the Treatment of AD-MCI Patients
NCT06470074AD-MCI
Xuanwu Hospital, Beijing
Not applicable
124
Beijing
2024-09
Active, closed
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
NCT06116136MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer
DrugsS095029·Pembrolizumab
Servier Bio-Innovation LLC
Phase 1/2
48
Beijing, Harbin, Zhengzhou, Shenyang, Jinan, Shanghai, Hangzhou
2024-08-31
Not yet open
A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS Syndrome
NCT06518876POEMS Syndrome
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
Phase 1
21
Beijing
2024-08-31
Active, closed
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
NCT06564142Immunoglobulin A Nephropathy
DrugPovetacicept
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Beijing, Cangzhou, Changchun, Changzhi, Chengdu, Chongqing, Dongguan, Foshan
2024-08-30
Recruiting
EASi-KIDNEYโ„ข (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824Kidney Disease, Chronic
DrugEmpagliflozin
Boehringer Ingelheim
Phase 3
11,000
Anshan, Beijing, Changzhi, Chaoyang, Chengdu, Chifeng, Chongqing, Foshan
2024-08-30
Recruiting
Study With [225Ac]Ac-FL-020 in mCRPC Participants
NCT06492122Metastatic Castration-resistant Prostate Cancer
Full-Life Technologies UK Limited
Phase 1
50
Beijing, Shanghai
2024-08-30
Recruiting
Unveiling the Neural Mechanisms of 5-HT7 in Sleep Apnea Induced by Arousal Dysregulation
NCT06608888Obstructive Sleep Apnea
Beijing Tsinghua Chang Gung Hospital
Observational
140
Beijing
2024-08-30
Recruiting
Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy
NCT06932744Paroxysmal Nocturnal Haemoglobinuria (PNH)
DrugsMY008211A·Eculizumab
Wuhan Createrna Science and Technology Co., Ltd
Phase 3
66
Beijing, Tianjin
2024-08-30
Recruiting
Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT06509009Nasopharyngeal Carcinoma by AJCC V8 Stage
DrugNimotuzumab
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
30
Beijing
2024-08-30
Recruiting
Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL
NCT06503263Diffuse Large B-cell Lymphoma
DrugZanubrutinib
Navy General Hospital, Beijing
Phase 2
240
Beijing
2024-08-30
Recruiting
Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
NCT06932471Paroxysmal Nocturnal Hemoglobinuria
DrugMY008211A
Wuhan Createrna Science and Technology Co., Ltd
Phase 3
20
Beijing
2024-08-30
Recruiting
Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.
NCT06440057Neuroendocrine Carcinoma
DrugZG006
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
78
Beijing
2024-08-29
Recruiting
Peginterferon ฮฑ-2b Injection for Hydroxyurea Resistant or Intolerant ET
NCT06552429Essential Thrombocythemia
DrugPeginterferon ฮฑ-2b
Xiamen Amoytop Biotech Co., Ltd.
Phase 2
27
Beijing, Fujian, Guangzhou, Harbin, Henan, Shanghai, Zhejiang
2024-08-29
Recruiting
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277Advanced Non-small Cell Lung Cancer, HER2 Mutation
DrugsSevabertinib·Pemetrexed·Cisplatin·Carboplatin
Bayer
Phase 3
444
Beijing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin, Wuhan, Changsha
2024-08-28
Active, closed
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
NCT06450197Moderate to Severe Crohn's Disease
DrugAZD7798
AstraZeneca
Phase 2
120
Beijing, Chengdu, Guangzhou, Hangzhou, Nanchang, Nanjing, Wuhan
2024-08-28
Active, closed
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
NCT06486441Endometrial Cancer
DrugsSacituzumab Govitecan·Doxorubicin·Paclitaxel
Gilead Sciences
Phase 3
640
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangxi Zhuang Autonomous Region, Guangzhou, Hangzhou
2024-08-28
By invitation
Long-term, High Blood Flow Hemoadsorption Therapy in Patients Undergoing Maintenance Hemodialysis
NCT06574425Chronic Kidney Diseases, Hemodialysis
Dongliang Zhang, MD
Phase 4
80
Beijing
2024-08-28
Active, closed
ARISE-A Chinese Real-world Study of Rimegepant for the Acute Treatment of Migraine
NCT06439628Migraine
DrugRimegepant
Chinese PLA General Hospital
Observational
3,000
Beijing, Hangzhou
2024-08-27
Active, closed
Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment
NCT06502977Extensive Stage Small Cell Lung Cancer
Amgen
Phase 2
32
Beijing, Chongqing, Fuzhou, Guangzhou, Jiangmen, Harbin, Wuhan, Tianjin
2024-08-27
Active, closed
Volrustomig Priming Regimens Exploratory Phase II Platform Study
NCT06448754Non-small Cell Lung Cancer
DrugsRamucirumab·Volrustomig·Pemetrexed·Paclitaxel
AstraZeneca
Phase 2
194
Beijing, Hangzhou, Jinan, Yantai, Zhengzhou
2024-08-27
Active, closed
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
NCT06564311Relapsing Multiple Sclerosis
DrugObexelimab
Zenas BioPharma (USA), LLC
Phase 2
93
Beijing, Suzhou, Tianjin, รœrรผmqi, Wuhan
2024-08-26
Recruiting
Efficacy of ICG-based NIR Imaging in Intralesional Curettage of Giant Cell Tumors of Bone in Limbs: a Prospective, Single-center, Single-arm, Open Study
NCT06647901Giant Cell Tumor of Bone
Tang Xiaodong
Phase 1/2
45
Beijing
2024-08-23
Active, closed
A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease
NCT06610526Chronic Kidney Disease
DrugDapagliflozin
AstraZeneca
Phase 4
731
Beijing, Changchun, Dongguan, Foshan, Fuyang, Fuzhou, Ganzhou, Harbin
2024-08-23
By invitation
A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC
NCT06863831Esophageal Squamous Cell Carcinoma (ESCC)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
536
Beijing
2024-08-22
Recruiting
China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)
NCT04974138Hypertension, MTHFR 677 CC or CT Genotype, Elevated Plasma Homocysteine (Hcyโ‰ฅ10ยตmol/L), Insufficient Plasma Folate Levels (<12ng/mL)
DrugsAmlodipine besylate·Amlodipine besylate and folic acid·Amlodipine
Shenzhen Ausa Pharmed Co.,Ltd
Phase 4
32,000
Bengbu, Bozhou, Chizhou, Fuyang, Beijing, Yangjiang, Guiyang, Huaihua
2024-08-22
Recruiting
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
NCT06535607Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy), Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)
DrugsVolrustomig·Ivonescimab·Paclitaxel·Cisplatin
AstraZeneca
Phase 2
257
Anyang, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dongguan
2024-08-22
By invitation
Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China
NCT06712017Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Non-Resectable
GrandPharma (China) Co., Ltd.
Observational
100
Guangzhou, Jinan, Xiโ€™an, Beijing, Shanghai
2024-08-22
Recruiting
China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT Genotype
NCT04974151Hypertension, MTHFR 677 TT Genotype
DrugsAmlodipine besylate·Amlodipine besylate and folic acid·Amlodipine
Shenzhen Ausa Pharmed Co.,Ltd
Phase 4
24,000
Bengbu, Bozhou, Chizhou, Fuyang, Beijing, Yangjiang, Guiyang, Huaihua
2024-08-22
Recruiting
TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer
NCT06532812Breast Cancer, Breast Carcinoma, Breast Cancer Metastatic, Breast Cancer Triple Negative
DrugsCyclophosphamid·Tumor Infiltrating Lymphocytes·Aldesleukin·Fludarabine
Essen Biotech
Phase 1/2
85
Beijing
2024-08-22
Recruiting
Large Segmentation Radiotherapy ยฑ Deep Inspiration Breath Hold(DIBH) for Left Breast Cancer
NCT06660628Breast Cancer
Peking Union Medical College Hospital
Not applicable
348
Beijing
2024-08-21
Not yet open
Priority-Matching Correction Technique in Degenerative Lumbar Scoliosis
NCT06470165Degenerative Lumbar Disease, Scoliosis, Degenerative Scoliosis
Xuanwu Hospital, Beijing
Not applicable
200
Beijing
2024-08-21
Recruiting
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
NCT06290141Chronic Inflammatory Demyelinating Polyneuropathy
DrugsRiliprubart·IVIG
Sanofi
Phase 3
160
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Jiazhuang, Jinan
2024-08-21
Recruiting
Sitagliptin or BeiDouGen Capsule Improve the Pregnancy Outcome in Patients with PCOS
NCT06587698Polycystic Ovarian Syndrome
DrugSitagliptin
Peking University Third Hospital
Not applicable
300
Beijing
2024-08-21
Recruiting
A Study of [177Lu] Lu-PSMA-XT Injection in Patients With Metastatic Prostate Cancer
NCT07096128mCRPC
Jinming Zhang
Phase 1
36
Beijing
2024-08-20
Recruiting
Research on Early Diagnosis and Clinical Transformation of Nuclide Probe Based on Bioorthogonal-gastric Cancer Mucin Target Visualization
NCT06429891Solid Tumor
Drug18F-FDG
Hua Zhu
Not applicable
50
Beijing
2024-08-20
Recruiting
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
NCT06538012Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Non-small Cell, Lung Cancer Recurrent
DrugsTumor Infiltrating Lymphocytes·Aldesleukin·Fludarabine·Cyclophosphamide
Essen Biotech
Phase 1/2
85
Beijing
2024-08-20
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
NCT06461897Atopic Dermatitis
DrugsUpadacitinib·Dupilumab
AbbVie
Phase 3
675
Beijing, Yuzhong District, Xiamen, Shenzhen, Zhengzhou, Changsha, Dalian, Chengdu
2024-08-19
By invitation
Smart Technology Facilitated Patient-centered Venous Thromboembolism Management
NCT06350331Venous Thromboembolism, Digital Health, Health Education
Navy General Hospital, Beijing
Not applicable
256
Beijing
2024-08-17
Recruiting
Safety and Efficacy of Fruquintinib Plus Chidamide and Sintilimab in the Third and Later Line Treatment of MSS/pMMR Metastatic Colorectal Cancer
NCT06685276Colorectal Cancer Metastatic
DrugsFruquintinib·Chidamide·Sintilimab
Dai, Guanghai
Phase 2
46
Beijing
2024-08-16
Recruiting
A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer
NCT07122414Non-muscle Invasive Bladder Cancer (NMIBC)
DrugFL115
Suzhou Forlong Biotechnology Co., Ltd
Phase 1/2
80
Beijing, Fuzhou, Wenzhou, Changsha, Nanjing, Suzhou, Qingdao, Chengdu
2024-08-16
Recruiting
Phase โ…ก Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer
NCT06708858Advanced Biliary Tract Cancer
DrugsSurufatinib·Durvalumab·Gemcitabine·Cisplatin
Dai, Guanghai
Phase 2
35
Beijing
2024-08-15
Not yet open
Effect of Aerobic Interval Training on Atrial Fibrillation Burden
NCT06491329Atrial Fibrillation, Cardiac Rehabilitation
Navy General Hospital, Beijing
Not applicable
156
Beijing
2024-08-15
By invitation
Application of FAPI Visualization in the Assessment of Right Ventricular Dysfunction Due to Volume Overload
NCT06663566Right Heart Insufficiency, Tricuspid Regurgitation
Beijing Anzhen Hospital
Observational
90
Beijing
2024-08-15
Recruiting
Phase II Study of FCN-159 in NF2 Nerve Sheath Tumors
NCT06553365Nerve Sheath Tumor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
30
Beijing
2024-08-15
Recruiting
One-Month DAPT in CABG Patients
NCT05997693Chronic Coronary Disease
DrugsTicagrelor·Aspirin
Weill Medical College of Cornell University
Phase 3
700
Shanghai, Changchun, Beijing
2024-08-15
Recruiting
Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC
NCT06467617Non Small Cell Lung Cancer
Beijing Chest Hospital, Capital Medical University
Phase 2
35
Beijing
2024-08-14
Recruiting
Weight Cycling on Hyperandrogenemia and Insulin Resistance in Polycystic Ovary Syndrome
NCT06545721Polycystic Ovary Syndrome
Peking Union Medical College Hospital
Not applicable
425
Beijing
2024-08-13
Active, closed
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06508658Diffuse Large B-Cell Lymphoma
DrugsEpcoritamab·Lenalidomide·Rituximab·Oxaliplatin
Genmab
Phase 3
379
Beijing, Fuzhou, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2024-08-13
Recruiting
Scoring Balloon and High Pressure Balloon in the Treatment of Arteriovenous Graft Stenosis
NCT06503692Arteriovenous Graft Stenosis
DK Medical Technology (Suzhou) Co., Ltd.
Not applicable
140
Beijing, Guangzhou, Shenzhen, Zhengzhou, Nanjing, Shanghai
2024-08-13
Recruiting
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
NCT06467357Biliary Tract Cancer
DrugsRilvegostomig·Trastuzumab deruxtecan·Durvalumab·Gemcitabine
AstraZeneca
Phase 3
620
Beijing, Bengbu, Changchun, Changde, Changsha, Chengdu, Chongqing, Fuzhou
2024-08-12
Active, closed
A Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy
NCT06516068Obstructive Hypertrophic Cardiomyopathy
Shandong Suncadia Medicine Co., Ltd.
Phase 2
42
Beijing
2024-08-11
Not yet open
Efficacy of Deep Brain Stimulation(DBS) for Treatment-Resistant Depression(TRD)
NCT06542900Treatment Resistant Depression
Xuanwu Hospital, Beijing
Not applicable
60
Beijing
2024-08-10
Recruiting
Evaluate the Efficacy and Safety of Amino Acid (15) Peritoneal Dialysis Solution in Peritoneal Dialysis Patients with Malnutrition.
NCT06597201End Stage Renal Disease (ESRD)
DrugAmino acid (15) peritoneal dialysis
Chengdu Qingshan Likang Pharmaceutical Co., Ltd
Phase 4
400
Hefei, Beijing, Wuhan, Changsha, Chengdu, Chongqing, Ganzhou, Guangdong
2024-08-09
Recruiting
ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI
NCT06388031Non-small Cell Lung Cancer
DrugPembrolizumab
Peking Union Medical College Hospital
Phase 2
27
Beijing
2024-08-09
Recruiting
Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT06332534Crohn's Disease
DrugUpadacitinib
AbbVie
Phase 3
110
Beijing, Guangzhou, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai, Hangzhou
2024-08-08
Recruiting
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
NCT06549595Untreated Follicular Lymphoma
DrugsSurovatamig·R-Chop
AstraZeneca
Phase 3
1,018
Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2024-08-07
Active, closed
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
NCT06531109Alopecia Areata
DrugRitlecitinib
Pfizer
Observational
450
Beijing, Changchun, Changsha, Guangzhou, Shanghai
2024-08-07
Recruiting
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
NCT06445972Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms, Esophageal Cancer
DrugsPatritumab Deruxtecan·Ramucirumab·Sacituzumab tirumotecan·Paclitaxel
Merck Sharp & Dohme LLC
Phase 1/2
210
Beijing, Fuzhou, Xiamen, Zhengzhou, Nanchang, Shanghai, รœrรผmqi, Hangzhou
2024-08-07
Active, closed
Polymeric Micellar Paclitaxel-Based Combination Therapy for Advanced Biliary Tract Cancer
NCT07159204Biliary Tract Cancer (BTC)
Peking Union Medical College Hospital
Phase 2
61
Beijing
2024-08-07
Recruiting
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
NCT06416410Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer
DrugsJAB-3312·Glecirasib·Pemetrexed·Tislelizumab
Allist Pharmaceuticals, Inc.
Phase 3
392
Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Cangzhou, Haerbin
2024-08-07
Active, closed
Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China
NCT06332014Osteoporosis
DrugProlia
Amgen
Phase 4
102
Beijing, Chongqing, Guangzhou, Harbin, Huaian, Nanjing, Suzhou, Xuzhou
2024-08-06
Recruiting
Al18F-NOTA-LM3 PET/CT in Patients With Pheochromocytoma and Paraganglioma
NCT07288931Pheochromocytoma/Paraganglioma (PPGL)
DrugsDiagnostic Test: 68Ga-DOTATATE·Diagnostic Test: Al18F-NOTA-LM3
Peking Union Medical College Hospital
Not applicable
40
Beijing
2024-08-06
Active, closed
Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNฮฑ Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
NCT06491563For Treatment of Chronic Hepatitis B Virus Infection
DrugsBRII-179·Elebsiran·PEG-IFNฮฑ
Brii Biosciences Limited
Phase 2
150
Beijing, Xiamen, Foshan, Guangzhou, Shenzhen, Shanghai, Chengdu, Hangzhou
2024-08-06
Active, closed
Iptacopan in Patients With ANCA Associated Vasculitis
NCT06388941Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
DrugsIptacopan·Rituximab
Novartis Pharmaceuticals
Phase 2
84
Shijiazhuang, Zhengzhou, Beijing
2024-08-05
Recruiting
Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer
NCT06433609Advanced Breast Cancer
Beijing GoBroad Hospital
Phase 2
113
Beijing
2024-08-05
Active, closed
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
NCT06492291Hypercholesterolemia
DrugEnlicitide Decanoate
Merck Sharp & Dohme LLC
Phase 3
3,000
Beijing, Chongqing, Guangzhou, Huizhou, Shenzhen, Jingzhou, Wuhan, Changsha
2024-08-05
Recruiting
Trial of JYB1904 in Chronic Spontaneous Urticaria.
NCT06509334Chronic Spontaneous Urticaria
DrugsJYB1904·Omalizumab
Jemincare
Phase 2
135
Beijing
2024-08-04
Active, closed
Study of CM310 in Adolescent Subjects With Atopic Dermatis
NCT06495229Atopic Dermatitis
DrugStapokibart
Keymed Biosciences Co.Ltd
Phase 3
180
Beijing
2024-08-02
Recruiting
Clinical Study on the Effectiveness of Diverse Segments Defocus Optimization in Spectacle Lenses for Slowing Myopia Progression
NCT07323251Children With Myopia, Treatment, Multizone Lens Design for Myopic Defocus, Visual Quality
Beijing Tongren Hospital
Not applicable
120
Beijing
2024-08-02
Recruiting
POASAC Study (Preoperative Anemia Severity and Classification Study)
NCT06499974Anemia
Peking Union Medical College Hospital
Observational
1,000
Wuhu, Beijing, Zhangzhou, Zunyi, Chifeng, Hohhot
2024-08-02
Recruiting
A Dual-targeting Tracer TATE-RGD for the Diagnosis of SSTR- and RGD- Positive Tumors
NCT06632860Iodine-resistant Thyroid Cancer, Meningioma, NETs
Drug18-FDG
Peking Union Medical College Hospital
Phase EARLY_PHASE1
40
Beijing
2024-08-01
Active, closed
An Observational Study of Subcutaneous Implantable Cardioverter Defibrillator in Patients with Hypertrophic Cardiomyopathy At High Risk of Sudden Cardiac Death
NCT06604169HCM - Hypertrophic Cardiomyopathy, S-ICD System (implantable Defibrillator)
China National Center for Cardiovascular Diseases
Observational
589
Beijing
2024-08-01
Active, closed
S365: A Multicenter Longitudinal Cohort of Sleep Health
NCT06760000Sleep Disorder, Sleep
Peking University
Observational
5,000
Beijing
2024-08-01
Active, closed
Efficacy and Safety of LP-003 Injection in Patients With Moderate to Severe Seasonal Allergic Rhinitis
NCT07291284Seasonal Allergic Rhinitis
DrugLP-003
Longbio Pharma
Phase 3
546
Beijing
2024-08-01
Not yet open
Effect of Low Molecular Heparin on Pregnancy Outcome With Protein S Deficiency
NCT06531525Pregnancy Related, Protein S Deficiency
DrugsEnoxaparin·Aspirin
Peking University People's Hospital
Phase 2
48
Beijing
2024-08-01
Recruiting
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751Advanced Breast Cancer
DrugsCamizestrant·Saruparib·Anastrozole·Exemestane
AstraZeneca
Phase 3
788
Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Foshan, Fuzhou
2024-08-01
Recruiting
Mechanisms of Brain-Heart Injury of Post-Intracranial Hemorrhage
NCT06906432Subarachnoid Hemorrhage, Aneurysmal, Cerebrocardiac Syndrome, Mass Spectrometry, Heart Failure
Beijing Tiantan Hospital
Observational
1,000
Beijing
2024-08-01
Recruiting
Investigation Into the Use of BAH243 Lentiviral Vector for Gene Therapy in Treating Sickle Cell Disease
NCT06399107Sickle Cell Disease, Sickle-Cell Disease With Crisis
Essen Biotech
Phase 1/2
85
Beijing
2024-08-01
Rows per page Showing 3201–3300 of 5484
Previous 31 32 33 34 35 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing?page=33

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5,484 of those studies with a site in Beijing.

How many clinical trials are recruiting in Beijing?

3,341 of the 5,484 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 966 have not yet opened recruitment, 1,001 are active but closed to new participants, and 176 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.